Thomas Hayman, MD, PhD
Assistant Professor of Therapeutic RadiologyCards
About
Research
Publications
2026
Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State
Ninia JG, Verma N, Long JB, Laird JH, Hicks DF, Hayman TJ, Knowlton CA, Campbell AM, Housri N, Peters GW, Al Feghali KA, de Jong D, Chiang AC, Park HS. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer: Outcomes Based on Completeness of Consolidation and Oligometastatic State. Clinical Lung Cancer 2026, 27 DOI: 10.1016/j.cllc.2026.03.009.Peer-Reviewed Original ResearchSTING predicts patterns of failure in locally advanced head and neck squamous cell carcinoma
MacNeil T, Hayman T, Li S, Moutafi M, Martinez-Morilla S, Vathiotis I, Hu R, Harari P, Burtness B, Liu H, Kimple R, Rimm D, Contessa J. STING predicts patterns of failure in locally advanced head and neck squamous cell carcinoma. JNCI Cancer Spectrum 2026, 10: pkaf126. PMID: 41569294, PMCID: PMC12972654, DOI: 10.1093/jncics/pkaf126.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalFemaleHead and Neck NeoplasmsHumansMaleMembrane ProteinsMiddle AgedOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckStromal CellsTissue Array AnalysisTreatment FailureConceptsTumor cellsSTING protein levelsDistant failureTissue microarrayPreclinical modelsStromal compartmentQuantitative immunofluorescenceAssociated with p16 positivityRisk of distant failureLocal controlLocal-regional controlLocal-regional recurrenceLocally advanced headPatterns of failureProtein levelsPrimary HNSCCP16-positiveHPV+ tumorsRadiation therapyTMA cohortTumor stromaSTING expressionTherapeutic resistanceHNSCCBorderline significance
2025
Role of PLK4 inhibition in cancer therapy
Banik K, Hayman T. Role of PLK4 inhibition in cancer therapy. Cancer And Metastasis Reviews 2025, 44: 55. PMID: 40512236, DOI: 10.1007/s10555-025-10271-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAssociated with more advanced diseaseCancer therapyAssociated with tumor progressionMore advanced diseasePolo-like kinase 4PLK4 overexpressionMultiple cancer typesAdvanced diseaseTherapeutic resistanceClinical outcomesTumor progressionSmall molecule inhibitorsHuman tumorsCancer typesDNA-damaging agentsSerine-threonine kinaseCancerOncogenic processesTherapeutic gainTherapeutic targetPolo-like kinase 4 inhibitorPLK4 inhibitionKinase 4Genomic instabilityTherapyPLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity
Dominguez-Vigil I, Banik K, Baro M, Contessa J, Hayman T. PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity. Molecular Cancer Therapeutics 2025, 24: 1350-1361. PMID: 40296663, PMCID: PMC12353405, DOI: 10.1158/1535-7163.mct-24-0978.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerCFI-400945Mitotic catastropheNon-small cell lung cancer radiosensitizationRadiosensitivity of NSCLC cell linesCentrosome amplificationRadiation-induced tumor growth delayPLK4 inhibitionCell deathCurative-intent chemoradiationIncreased G2/M cell cycle arrestPolo-like kinase 4Subtype of lung cancerCell lung cancerIncreased centrosome amplificationCancer-related mortalityG2/M cell cycle arrestNSCLC cell linesCell cycle phase distributionClinical trial evaluationTargeting PLK4NSCLC in vitroCell cycle arrestPotential therapeutic target
2024
Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity
Hayman T. Rethinking the use of germline CHEK2 mutation as a marker for PARP inhibitor sensitivity. JNCI Cancer Spectrum 2024, 8: pkae045. PMID: 38950525, PMCID: PMC11216723, DOI: 10.1093/jncics/pkae045.Commentaries, Editorials and LettersRadioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically Effective DoseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failure
2023
Iron homeostasis governs erythroid phenotype in Polycythemia Vera
Bennett C, Jackson V, Pettikiriarachchi A, Hayman T, Schaeper U, Moir-Meyer G, Fielding K, Ataide R, Clucas D, Baldi A, Garnham A, Li-Wai-Suen C, Loughran S, Baxter E, Green A, Alexander W, Bahlo M, Burbury K, Ng A, Pasricha S. Iron homeostasis governs erythroid phenotype in Polycythemia Vera. Blood 2023, 141: 3199-3214. PMID: 36928379, PMCID: PMC10646816, DOI: 10.1182/blood.2022016779.Peer-Reviewed Original ResearchConceptsGenome-wide association studiesIron homeostasisErythroid phenotypePolycythemia veraRegulator of systemic iron homeostasisGenetic dissectionAssociation studiesSystemic iron homeostasisUK Biobank dataHFE variantsErythroid diseaseMouse model of PVExpression of hepcidinBiobank dataLife-threatening thrombotic eventsActivating mutationsHepcidin expressionPathophysiology of PVPhenotypeHomeostasisMyeloproliferative neoplasmsThrombotic eventsHepcidin upregulationTherapeutic strategiesInflammatory cytokines
2021
Zinc Supplementation with or without Additional Micronutrients Does Not Affect Peripheral Blood Gene Expression or Serum Cytokine Level in Bangladeshi Children
Hayman T, Hickey P, Amann-Zalcenstein D, Bennett C, Ataide R, Sthity R, Khandaker A, Islam K, Stracke K, Yassi N, Watson R, Long J, Westcott J, Krebs N, King J, Black R, Islam M, McDonald C, Pasricha S. Zinc Supplementation with or without Additional Micronutrients Does Not Affect Peripheral Blood Gene Expression or Serum Cytokine Level in Bangladeshi Children. Nutrients 2021, 13: 3516. PMID: 34684517, PMCID: PMC8541127, DOI: 10.3390/nu13103516.Peer-Reviewed Original ResearchConceptsPeripheral blood gene expressionMultiple micronutrient powdersBlood gene expressionZinc supplementationZinc interventionCytokine levelsCommunity-based efficacy trialDispersible tabletsImpact of zinc supplementationEffect of zinc supplementationSerum cytokine levelsGene expressionPreventive zinc supplementationDetect cytokine profilesSensitive multiplex assayMonths of agePlacebo powderCytokine profileImmune profilePeripheral bloodCytokine signatureHome fortificationCytokine concentrationsMicronutrient powderZinc deficiencySTING enhances cell death through regulation of reactive oxygen species and DNA damage
Hayman TJ, Baro M, MacNeil T, Phoomak C, Aung TN, Cui W, Leach K, Iyer R, Challa S, Sandoval-Schaefer T, Burtness BA, Rimm DL, Contessa JN. STING enhances cell death through regulation of reactive oxygen species and DNA damage. Nature Communications 2021, 12: 2327. PMID: 33875663, PMCID: PMC8055995, DOI: 10.1038/s41467-021-22572-8.Peer-Reviewed Original ResearchThe translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress
Phoomak C, Cui W, Hayman TJ, Yu SH, Zhao P, Wells L, Steet R, Contessa JN. The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress. Science Advances 2021, 7: eabc6364. PMID: 33523898, PMCID: PMC7810369, DOI: 10.1126/sciadv.abc6364.Peer-Reviewed Original ResearchTranslocon-associated proteinN-glycosylationER stressER glycoprotein quality controlTranslocon-associated protein complexEndoplasmic reticulum (ER) homeostasisAberrant N-glycosylationGlycoprotein quality controlER chaperone BiPFluorescence-based strategyProtein complexesPosttranslational modificationsChaperone BiPTRAP complexGlycosylation defectsConditions of stressRegulatory roleTranscriptional signatureIndividual cellsDownstream ERProtein levelsSubunitsSSR3GlycosylationCells
Clinical Care
Overview
Thomas Hayman, MD, PhD, is a therapeutic radiologist who specializes in treating cancers of the lung, head and neck, skin, and more. He employs advanced radiation techniques, including stereotactic radiosurgery and intensity-modulated radiation therapy (which uses precise computer planning to target tumors), to manage various malignancies such as those in the central nervous system, prostate, and gastrointestinal tract.
As an assistant professor of therapeutic radiology at Yale School of Medicine, Dr. Hayman studies how cancer cells resist damage from radiation. He aims to discover better ways to overcome these defenses, ultimately translating new findings into clinical practice.
Dr. Hayman received his medical degree and doctoral degree from the University of South Florida Morsani College of Medicine. He completed a residency in radiation oncology at Yale New Haven Hospital.
Clinical Specialties
Fact Sheets
Merkel Cell Carcinoma (MCC)
Learn More on Yale MedicineHead and Neck Cancer
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineRhabdomyosarcoma
Learn More on Yale Medicine
Board Certifications
Radiation Oncology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 2021
Yale Medicine News
News & Links
Get In Touch
Contacts
Therapeutic Radiology
Yale University PO Box 208040
New Haven, CT 06513
United States
Locations
Yale Therapeutic Radiology
Academic Office
Hunter Building
15 York Street, Ste H213E
New Haven, CT 06510
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.